Home Cart Sign in  
Chemical Structure| 212844-53-6 Chemical Structure| 212844-53-6

Structure of Purvalanol A
CAS No.: 212844-53-6

Chemical Structure| 212844-53-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Purvalanol A is a CDK2 inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, respectively.

Synonyms: NG-60

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Purvalanol A

CAS No. :212844-53-6
Formula : C19H25ClN6O
M.W : 388.89
SMILES Code : CC(C)[C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO
Synonyms :
NG-60
MDL No. :MFCD02179211
InChI Key :PMXCMJLOPOFPBT-HNNXBMFYSA-N
Pubchem ID :456214

Safety of Purvalanol A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Purvalanol A

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK4

    CDK4/CyclinD1, IC50:850 nM

  • CDK2

    CDK2/CyclinE, IC50:35 nM

    CDK2/CyclinA, IC50:70 nM

  • Cdc

    Cdc2/CyclinB, IC50:4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human foreskin fibroblasts (HFFs) 20 μM 2 days To evaluate the antiviral effects of Purvalanol A on VZV replication, results showed that Purvalanol A exhibited antiviral activity in cultured HFFs. PMC2866756
HeLa cells 25 μM 2 hours To investigate the effect of Purvalanol A on mitotic exit in HeLa cells in the presence of MG132, results showed that Purvalanol A was unable to drive mitotic exit. PMC2080905
Jurkat cells 20 µM 24 hours Purvalanol A repressed the levels of DHFR protein and enhanced sensitivity to MTX in Jurkat cells. PMC11158204
Giardia lamblia 10 µM 24 hours To study the effect of Purvalanol A on Cdk2 kinase activity. Results showed that addition of purvalanol A significantly decreased the Cdk2-associated kinase activity. PMC3281681
Human umbilical vein endothelial cells 10 µM 30 minutes to 1 hour To investigate the effect of Purvalanol A on CA-4-P-induced mitotic arrest, results showed that Purvalanol A accelerated the progression of cells through mitosis. PMC3118836
Tet-BZLF1/Akata cells 5 μM 48 hours Inhibited EBV lytic protein expression, almost completely blocking viral protein production PMC303396
C. elegans embryos 100 mM 5 minutes To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening. PMC3216336
Kasumi-1 0.1 µM and 0.5 µM 72 hours To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on Kasumi-1 cells. Results showed that the combination significantly increased cell death compared to single agents. PMC10058112
MV4-11 0.1 µM and 0.5 µM 72 hours To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on MV4-11 cells. Results showed that the combination significantly increased cell death compared to single agents. PMC10058112
CMK 0.1 µM and 0.5 µM 72 hours To evaluate the cytotoxicity of Purvalanol A in combination with ABT-737 on CMK cells. Results showed that the combination significantly increased cell death compared to single agents. PMC10058112
Tet-BZLF1/B95-8 cells 15 μM 72 hours Inhibited EBV lytic replication, almost completely blocking viral DNA amplification PMC303396
MV4-11 cells 1.3 μM 72 hours Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity. PMC11480974
MOLM-13 cells 1.3 μM 72 hours Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity. PMC11480974
MOLM-14 cells 1.3 μM 72 hours Evaluate the effects of Purvalanol A alone or in combination with ABT-737 on cell viability, showing that the combined treatment significantly enhanced cytotoxicity. PMC11480974
HPV31b-positive keratinocytes 10 nM from day 8 to day 12 Inhibition of CDK1 kinase activity resulted in the synthesis of noninfectious HPV31b particles PMC2863740

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C. elegans Wild-type and APC mutant embryos Uterine injection 100 mM Single injection, lasting 5 minutes To study the effect of CDK-1 inhibition on meiotic spindle rotation, results showed that PA treatment caused spindle rotation and shortening. PMC3216336
SCID-Hu mice Skin xenograft model Intraperitoneal injection 20 mg/kg/day and 10 mg/kg/day Once daily for 7 days To evaluate the antiviral effects of Purvalanol A in the SCID-Hu mouse model, results showed that Purvalanol A failed to effectively inhibit VZV replication. PMC2866756

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.86mL

2.57mL

1.29mL

25.71mL

5.14mL

2.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories